579 related articles for article (PubMed ID: 31322019)
1. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
2. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
3. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
4. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
6. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
8. Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources.
Youn B; Proud CM; Wang N; Hou Q; Viscidi E; Eaton S; Paradis AD; Neville BA; Johnson NB
Adv Ther; 2023 Mar; 40(3):1129-1140. PubMed ID: 36645543
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
10. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
11. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
[TBL] [Abstract][Full Text] [Related]
12. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
[TBL] [Abstract][Full Text] [Related]
13. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
[TBL] [Abstract][Full Text] [Related]
14. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
Watson C; Xu H; Princic N; Sruti I; Barlev A
J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of spinal muscular atrophy.
Armstrong EP; Malone DC; Yeh WS; Dahl GJ; Lee RL; Sicignano N
J Med Econ; 2016 Aug; 19(8):822-6. PubMed ID: 27264163
[TBL] [Abstract][Full Text] [Related]
16. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
17. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
19. Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy.
Vukovic S; McAdam L; Zlotnik-Shaul R; Amin R
J Paediatr Child Health; 2019 Jan; 55(1):18-24. PubMed ID: 30246272
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]